# EXACT SCIENCES CORP (EXAS) — merger/definitive [completed]
Source: SEC API (secapi.ai) · situation sit_80a8fff0b8da6c3adf5a · retrieved 2026-08-11T16:14:35.958Z

## Overview
Exact Sciences Corporation is a leading provider of cancer screening and diagnostics tests, including the Cologuard colorectal cancer screening test and Oncotype DX precision oncology portfolio, along with innovative solutions like Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease monitoring.

Abbott Laboratories agreed to acquire Exact Sciences Corporation in an all-cash merger for $105.00 per share, representing a 51% premium to Exact's unaffected closing price on November 18, 2025 (the last full trading day before news of the deal). Under the Merger Agreement dated November 19, 2025, Merger Sub (a wholly owned Abbott subsidiary) will merge with and into Exact, with Exact continuing as the surviving corporation and becoming a direct wholly owned subsidiary of Abbott. Each outstanding share of Exact common stock will be converted into the right to receive $105.00 in cash at the Effective Time, without interest and subject to tax withholding. The transaction is not conditioned on financing, with Abbott representing it has sufficient cash to complete the acquisition. Exact stockholders must approve the Merger Agreement by majority vote at a special meeting scheduled for February 20, 2026.

## Terms
- Counterparty: Abbott Laboratories · Deal value: $20.04B · Consideration: cash · Premium: 51.0% · Price/share: $105

## Key dates
- Announced 2026-01-09 · Record 2026-01-09 · Vote 2026-02-20 · Expected close 2026-06-30 · Completed 2026-03-23

## Timeline
- 2026-01-09 · DEFM14A (0001193125-26-008315): DEFM14A - EXACT SCIENCES CORP — *Exact Sciences Corporation is a leading provider of cancer screening and diagnostics tests, including the Cologuard colorectal cancer screening test and Oncotype DX precision oncology portfolio, along with innovative solutions like Cancerguard for multi-cancer early detection and Oncodetect for molecular residual disease monitoring.* Abbott Laboratories agreed to acquire Exact Sciences Corporation in an all-cash merger for $105.00 per share, representing a 51% premium to Exact's unaffected closing price on November 18, 2025 (the last full trading day before news of the deal). Under the Merger Agreement dated November 19, 2025, Merger Sub (a wholly owned Abbott subsidiary) will merge with and into Exact, with Exact continuing as the surviving corporation and becoming a direct wholly owned subsidiary of Abbott. Each outstanding share of Exact common stock will be converted into the right to receive $105.00 in cash at the Effective Time, without interest and subject to tax withholding. The transaction is not conditioned on financing, with Abbott representing it has sufficient cash to complete the acquisition. Exact stockholders must approve the Merger Agreement by majority vote at a special meeting scheduled for February 20, 2026.
  https://www.sec.gov/Archives/edgar/data/1124140/0001193125-26-008315.txt
- 2026-03-23 · 8-K (0001193125-26-118700): 8-K 8-K
  https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/d128802d8k.htm

## Citations
- 0001193125-26-008315 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526008315
- 0001193125-26-118700 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526118700